Exelixis (EXEL) Q3 2026 Earnings Call Transcript
Exelixis reported Q3 2026 revenues of $659M, with cabozantinib franchise U.S. net product revenues at $605M, up 11% YoY. Global revenues reached $818M. Zanzalintinib is a key growth driver, with multiple trials advancing. GAAP net income was $218M ($0.88 per share). The company updated full-year guidance and repurchased $250M in stock.
How this was made
The 30-second read
Why it matters
Near-term trading is driven by the updated full-year gross-to-net deductions estimate, Q3 revenue/EPS prints, and capital return via share repurchases, while longer-term sentiment depends on zanza pivotal trial execution and enrollment.
Market read
Traders get a fresh earnings datapoint set plus an explicit full-year gross-to-net deductions update, alongside capital return and pipeline execution commentary.
What to watch
The excerpt emphasizes zanza trial activation/enrollment and Wave 2 planning, but without disclosed readouts; traders may overreact to financial mechanics versus pipeline optionality.
Background
Exelixis’ Q3 2026 earnings call discusses progress toward oncology franchise expansion, including zanza development and CABOMETYX (cabozantinib) franchise performance.
Ticker impact
Exelixis reported Q3 2026 results and updated full-year 2026 gross-to-net deductions to about 30%, plus $250M of share repurchases.
Likely modest pressure or volatility as investors reprice the updated gross-to-net and tax assumptions, partially offset by the ongoing buyback and strong CABO revenue growth.
The article includes specific Q3 revenue/EPS, gross-to-net change drivers, and an explicit full-year gross-to-net update, which are direct inputs to earnings power. However, it is a transcript and the excerpt does not include new clinical efficacy or regulatory outcomes.
Market effects
Reinforces investor focus on TKI franchise durability and gross-to-net management (340B discounts) for oncology pharma.
Primarily US-listed biotech sentiment, with limited direct regional spillover beyond healthcare equities.
Global partner royalty flows (Ipsen, Takeda) highlight cross-border revenue sensitivity to pricing and access programs.
Counterpoint
The gross-to-net deterioration may be temporary (driven by 340B discount timing), so the full-year 30% estimate could be less bearish than it appears.
Key entities
- companyExelixis
Oncology-focused biopharma reporting Q3 2026 results, updating full-year gross-to-net deductions, and discussing zanza and CABOMETYX franchise progress.
- product/franchiseCABOMETYX (cabozantinib) franchise
Reported Q3 2026 U.S. net product revenues of $605 million and global net product revenues of $818 million, with gross-to-net dynamics tied to 340B discounts.
- pipeline assetzanza (zanzalintinib)
Positioned as a potential second franchise molecule, with STELLAR-316 Phase III trial sites activated and enrolling.
- clinical trialSTELLAR-316 trial
Phase III pivotal trial in resected Stage II/III colorectal cancer using Signatera test selection; sites activated and enrolling (per excerpt).
